+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Impact of extensively drug-resistant tuberculosis on treatment outcome of multidrug-resistant tuberculosis patients with standardized regimen: report from Iran

Impact of extensively drug-resistant tuberculosis on treatment outcome of multidrug-resistant tuberculosis patients with standardized regimen: report from Iran

Microbial Drug Resistance 16(1): 81-86

The limited experience in treating patients with extensively drug-resistant tuberculosis (XDR-TB) shows a therapeutic success rate under 50-60% and there are no publications regarding the outcome of these patients treated with standardized regimens. All multidrug-resistant tuberculosis (MDR-TB) patients hospitalized at the Masih Daneshvari Hospital in Tehran, Iran, during 2004-2007 were recruited. Drug susceptibility testing to 14 drugs (including eight second-line drugs) was performed and a standardized regimen with ofloxacin, cycloserine, prothionamide, and amikacin was administered for all patients. Outcome of the patients was studied, comparing between the MDR-TB non-XDR-TB and the XDR-TB. Fifty-one patients were included, 12 with XDR-TB criteria. Of 51, 48 were HIV negative and HIV status was unknown in three cases. All 12 were HIV negative. XDR-TB infection was significantly associated only with age (p = 0.039). The success rates for the total 51 MDR-TB, the 39 MDR-TB non-XDR-TB, and the 12 XDR-TB patients were 76.5% (39 patients), 87.2% (34 patients), and 41.7% (5 patients), respectively. Resistance to ofloxacin, ciprofloxacin, and amikacin were found to be significantly associated with unsuccessful outcome. In this setting, a standardized second-line drugs regimen produces high treatment success rates in MDR-TB patients unless XDR-TB is present.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 053716412

Download citation: RISBibTeXText

PMID: 20192820

DOI: 10.1089/mdr.2009.0073

Related references

Prevalence of multidrug-resistant and extensively drug-resistant tuberculosis in patients with pulmonary tuberculosis in zahedan, southeastern iran. Iranian Red Crescent Medical Journal 14(1): 53-55, 2012

Adverse effects of multidrug-resistant tuberculosis treatment with a standardized regimen: a report from Iran. American Journal of Therapeutics 18(2): E29-E34, 2011

Treatment outcome of standardized regimen in patients with multidrug resistant tuberculosis. Journal of Pharmacology and Pharmacotherapeutics 5(2): 145-149, 2014

Low Levels of Extensively Drug-resistant Tuberculosis among Multidrug Resistant Tuberculosis Isolates and Their Relationship to Risk Factors: Surveillance in Tehran, Iran; 2006 to 2014. Osong Public Health and Research Perspectives 8(2): 116-123, 2017

Sequence analyses of just four genes to detect extensively drug-resistant Mycobacterium tuberculosis strains in multidrug-resistant tuberculosis patients undergoing treatment. Antimicrobial Agents and ChemoTherapy 53(8): 3353-3356, 2009

High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimen. European Respiratory Journal 2018, 2018

Effectiveness and Safety of Imipenem-Clavulanate Added to an Optimized Background Regimen (OBR) Versus OBR Control Regimens in the Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis. Clinical Infectious Diseases 62(9): 1188-1190, 2017

Multidrug-resistant tuberculosis in panama is driven by clonal expansion of a multidrug-resistant Mycobacterium tuberculosis strain related to the KZN extensively drug-resistant M. tuberculosis strain from South Africa. Journal of Clinical Microbiology 51(10): 3277-3285, 2014

Clinical outcome of multidrug-resistant tuberculosis patients receiving standardized second-line treatment regimen in China. Journal of Infection 76(4): 348-353, 2018

Extensively drug-resistant tuberculosis treatment outcome in Iran: a case series of seven patients. International Journal of Infectious Diseases 14(5): E399-E402, 2010

Evaluation of treatment outcome and adverse drug reaction of directly observed treatment (DOT) plus regimen in multidrug-resistant tuberculosis (MDR-TB) patients at district tuberculosis centre Rajkot. Perspectives in Clinical Research 9(4): 165-169, 2018

Additional drug resistance in Mycobacterium tuberculosis isolates from resected cavities among patients with multidrug-resistant or extensively drug-resistant pulmonary tuberculosis. Clinical Infectious Diseases 54(6): E51-E54, 2012

Tuberculosis burden in households of patients with multidrug-resistant and extensively drug-resistant tuberculosis: a retrospective cohort study. Lancet 377(9760): 147-152, 2011

Prevalence of extensively drug-resistant tuberculosis among patients with multidrug-resistant tuberculosis: a retrospective hospital-based study. Indian Journal of Medical Research 130(4): 392-395, 2010

Treatment of multidrug-resistant and extensively drug-resistant tuberculosis in adolescent patients. Pediatric Infectious Disease Journal 33(6): 657-659, 2015